Heptares enters a research and drug discovery collaboration with Juntendo University

04-Sep-2017 - United Kingdom

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT initiative with Juntendo University in Tokyo, Japan.

The new collaboration, Heptares’ fourth ORBIT programme, is with the research group of Professor Takehiko Yokomizo, an expert on Molecular Biology, Immunology and Cell Biology and Professor of Department of Molecular and Cellular Biochemistry at Juntendo University. The collaboration is the first international industrial partnership for this prestigious university. Research activities will focus on the bespoke design and profiling of novel leukotriene receptor modulators with potential therapeutic utility in intractable skin/intestinal ulcers.

Fiona Marshall, Chief Scientific Officer of Heptares, said: “We are delighted to collaborate with Professor Yokomizo and his group at Juntendo University. Their extensive experience and knowledge of leukotriene receptors, combined with our own structure-based design expertise, forms a strong basis from which to generate novel selective, small molecules with the potential to address difficult-to-treat wounds. We look forward to a productive relationship.”

Prof. Yokomizo, Juntendo University, added: “Heptares has a strong global reputation based on its GPCR drug design capabilities. We are excited to collaborate on this new project, which has the potential to significantly advance our knowledge of the links between leukotriene receptor and disease, and to progress new drug design strategies in this area.”

https://www.bionity.com/en/news/164680/heptares-enters-a-research-and-drug-discovery-collaboration-with-juntendo-university.html